Processa Pharmaceuticals, Inc. (PCSA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Processa Pharmaceuticals reported revenue of $0. Net income was -$13.6M, or -$10.36 per diluted share. Operating activities generated -$11.4M of cash, leaving -$11.4M of free cash flow. At fiscal year end, Processa Pharmaceuticals held $7.8M in total assets against $2.2M in total liabilities, including $5.5M of cash and equivalents.
Open the full interactive Processa Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Processa Pharmaceuticals Key Stats
| Share Price | $1.77 |
|---|---|
| Market Cap | $4.9M |
| 52-Week Range | $1.35 – $11.02 |
| Shares Outstanding | 2.8 million (basic, 2026 Q2) |
Processa Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$15.1M | -$12.1M | -$27.5M | -$11.5M | -$12.1M | -$14.0M |
| Pre-Tax Income | -$15.4M | -$12.0M | -$27.4M | -$11.1M | -$11.9M | -$13.6M |
| Income Tax | -$1.0M | -$530,611 | — | — | — | — |
| Net Income | -$14.4M | -$11.4M | -$27.4M | -$11.1M | -$11.9M | -$13.6M |
| Diluted EPS | -$1270.00 | -$375.00 | — | -$212.00 | -$96.75 | -$10.36 |
Processa Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$3.4M | -$3.4M | -$3.4M | -$3.3M |
| Diluted EPS | -$1.75 | -$2.57 | -$1.29 | -$1.19 |
Processa Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.4M | $16.5M | $6.5M | $4.7M | $1.2M | $5.5M |
| Current Assets | $16.2M | $18.3M | $8.4M | $5.6M | $1.9M | $5.7M |
| Total Assets | $25.2M | $26.5M | $8.6M | $5.8M | $3.2M | $7.8M |
| Current Liabilities | $1.2M | $971,020 | $998,556 | $730,579 | $1.5M | $2.2M |
| Total Long-Term Debt | $162,459 | — | — | — | — | — |
| Total Liabilities | $2.3M | $978,405 | $1.1M | $797,484 | $1.5M | $2.2M |
| Shareholders' Equity | $22.9M | $25.5M | $7.5M | $5.0M | $1.7M | $5.6M |
Processa Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$3.1M | -$8.7M | -$9.6M | -$8.1M | -$11.2M | -$11.4M |
| Cash From Investing | — | — | — | -$2,776 | -$3,244 | -$850,000 |
| Cash From Financing | $17.9M | $9.8M | -$388,843 | $6.3M | $7.7M | $16.6M |
| Free Cash Flow | — | — | -$9.6M | -$8.1M | -$11.2M | -$11.4M |
Figures from Processa Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Processa Pharmaceuticals financials page for every line item.
Processa Pharmaceuticals Company Profile
| Ticker | PCSA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Vero Beach, Florida |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001533743 |
Frequently Asked Questions
What was Processa Pharmaceuticals' revenue in fiscal 2025?
Processa Pharmaceuticals (PCSA) reported revenue of $0 for fiscal 2025.
What is Processa Pharmaceuticals' annual revenue history?
Processa Pharmaceuticals' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Processa Pharmaceuticals' net income in fiscal 2025?
Processa Pharmaceuticals reported net income of -$13.6M for fiscal 2025.
What was Processa Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Processa Pharmaceuticals' diluted EPS was -$10.36 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Processa Pharmaceuticals generate in fiscal 2025?
Processa Pharmaceuticals generated -$11.4M of free cash flow in fiscal 2025.
What was Processa Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Processa Pharmaceuticals reported revenue of $0.
How many shares of Processa Pharmaceuticals are outstanding?
Processa Pharmaceuticals reported a weighted average of 2.8 million basic shares outstanding in 2026 Q2.
What is Processa Pharmaceuticals' market cap?
Based on its latest closing price, Processa Pharmaceuticals (PCSA) has a market capitalization of about $4.9M.
When does Processa Pharmaceuticals' fiscal year end?
Processa Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Processa Pharmaceuticals headquartered?
Processa Pharmaceuticals lists its business address in Vero Beach, Florida in its SEC filings.